Scholarlink

<p>The introduction of targeted biologics (e.g., anti-IL-4/13 antibodies such as dupilumab, anti-IL-12/23, anti-TNF-alpha antibodies) and oral Janus kinase inhibitors (JAKi) have revolutionized the treatment of severe dermatological diseases in children in recent years. However, intervening in the child’s immune system also raises specific questions regarding vaccination planning and potential interactions, particularly concerning immunogenicity, safety (especially of live vaccines), and the timing of pre- and post-initiation therapy. This review summarizes current evidence and recommendations and aims to provide practical guidance for pediatrics and pediatric dermatology.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Pädiatrische Impfungen unter immunmodulierender Therapie dermatologischer Erkrankungen

  • 期刊论文

  • 发表日期：

    2026年1月22日

查看全文
  • Susanne Diesner-Treiber

摘要

The introduction of targeted biologics (e.g., anti-IL-4/13 antibodies such as dupilumab, anti-IL-12/23, anti-TNF-alpha antibodies) and oral Janus kinase inhibitors (JAKi) have revolutionized the treatment of severe dermatological diseases in children in recent years. However, intervening in the child’s immune system also raises specific questions regarding vaccination planning and potential interactions, particularly concerning immunogenicity, safety (especially of live vaccines), and the timing of pre- and post-initiation therapy. This review summarizes current evidence and recommendations and aims to provide practical guidance for pediatrics and pediatric dermatology.